Potential for Discovery: Opens up opportunities to explore new treatments for joint health, cardiovascular diseases, and chronic pain
This should be obvious, but its a corner that sometimes gets cut to save time or resources
For injection use, look for 99% purity with a Certificate of Analysis (COA) from an independent lab
The answer depends on multiple factors, including weight loss goals, comorbidities, patient preferences, cost considerations, and tolerance for different side effect profiles
2023;13(4)e23.00506
Key Facts Although the drugs were first approved for Type 2 diabetes maintenance, they were approved for weight loss in recent years, and research has shown they cause significant results: Tirzepatide typically causes patients to lose an average of 22.5% of body fat, while semaglutide causes a 15% reduction